Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the assessment of Lescol in Renal Transplantation trial

Transplantation

Volumn 79, Issue 9, 2005, Pages 1160-1163

  Fellström, Bengt ^a,i   Jardine, Alan G ^b   Soveri, Inga ^a   Cole, Edward ^c   Grönhagen Riska, Carola ^d   Neumayer, Hans H ^e   Maes, Bart ^f   Gimpelewicz, Claudio ^g   Holdaas, Hallvard ^h  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g NOVARTIS PHARMA AG   (Switzerland)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cardiovascular disease; Mortality; Renal transplant function; Risk factor

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; FLUINDOSTATIN; PREDNISOLONE;

ADULT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT FAILURE; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; STROKE;

ADULT; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; FATTY ACIDS, MONOUNSATURATED; HEART DISEASES; HUMANS; INDOLES; KIDNEY; KIDNEY TRANSPLANTATION; PLACEBOS; RISK FACTORS;

EID: 18644383407     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000160764.35083.B8     Document Type: Conference Paper

References (25)

1. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60(5): 451.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3):S112.
3. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356(9224): 147.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42(5): 1050.
5. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11(9): 1735.
6. Horl WH, Riegel W, Wanner C, et al. Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr 1989; 67(17): 907.
7. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55(5): 1899.
8. Annuk M, Zilmer M, Lind L, et al. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12(12): 2747.
9. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62(5): 1524.
10. Martola L, Elinder CG, Stenvinkel P. Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes. Lakartidningen 2003; 100(50): 4180.
11. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41(8): 1364.
12. Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. N Engl J Med 2004; 351(13): 1285.
13. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62(1): 311.
14. Woo YM, Jardine AG, Clark AF, et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999; 55(2): 692.
15. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001; 8(2): 63.
16. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361(9374): 2024.
17. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997; 28(3): 557.
18. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296.
19. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75(8): 1291.
20. Fellstrom B, Jardine A, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2004. Submitted.
21. Fellstrom B, Holdaas H, Jardine A, et al. Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial. Transplantation 2005; 79: 205.
22. Meier-Kriesche HU, Kaplan B. Death after graft loss: a novel endpoint for renal transplantation. Transplant Proc 2001; 33(7-8): 3405.
23. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47(1): 186.
24. Van Buren DH, Burke JF, Lewis RM. Renal function in patients receiving long-term cyclosporine therapy. J Am Soc Nephrol 1994; 4(8 Suppl): S17.
25. Bennett WM, DeMattos A, Meyer MM, Submitted. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50(4): 1089.